What is the investment case, and what must be true for it to hold?
Aura Life Science's investment case is an early-stage platform bet: the Chicago-based startup is at an early commercialization stage, short of revenue-scale manufacturing, emphasizing platform validation, pilot partnerships, and accelerator participation. It is building a photosynthetic biomanufacturing platform for carbon-negative production of proteins, enzymes, ingredients, and related industrial inputs.
Aura Life Science secured its first investment in 2026, a $100,000 LabStart Phase 2 investment, and mHUB said the company planned to open a pre-seed round in early 2026.
Which risks could break the thesis, and what would warn of them?
Aura Life Science's recombinant protein plans hinge on carrying its laboratory work into pilot production, and uneven protein output at that pilot scale would undercut the thesis. The company engineers photosynthetic strains to channel light-driven activity into recombinant protein output as it scales up from the lab.
Aura Life Science co-founder and CSO Jacob Bhoi was selected for Argonne's CRI 2026 cohort. The cohort provides research facilities, technical expertise and commercialization support.
What does the product do for its buyer, and how is it delivered?
Aura Life Science converts light and carbon dioxide into high-value enzymes using photosynthetic microbes, and it offers manufacturing partnerships and technology licensing opportunities.
Cyanobacteria need only sunlight and carbon dioxide to grow, whereas E. coli and yeast depend on costly sugar feedstocks. Through adjustments to the cyanobacterial circadian clock, Aura Life Science has raised recombinant protein expression 30-50 fold over wild-type strains.
Aura Life Science's platform technology enables the production of a diverse range of protein products across multiple industries.

Aura Life Science is a protein producer using photosynthetic microbes to make proteins from light and carbon dioxide.